Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

251R-1

Sigma-Aldrich

Factor XIIIa (EP3372) Rabbit Monoclonal Primary Antibody

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Código UNSPSC:
12352203
NACRES:
NA.41

fonte biológica

rabbit

Nível de qualidade

100
500

conjugado

unconjugated

forma do anticorpo

culture supernatant

tipo de produto de anticorpo

primary antibodies

clone

EP3372, monoclonal

descrição

For In Vitro Diagnostic Use in Select Regions (See Chart)

Formulário

buffered aqueous solution

reatividade de espécies

human

embalagem

vial of 0.1 mL concentrate (251R-14)
vial of 0.5 mL concentrate (251R-15)
bottle of 1.0 mL predilute (251R-17)
vial of 1.0 mL concentrate (251R-16)
bottle of 7.0 mL predilute (251R-18)

fabricante/nome comercial

Cell Marque®

técnica(s)

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:100-1:500

Isotipo

IgG

controle

dermatofibroma

Condições de expedição

wet ice

temperatura de armazenamento

2-8°C

visualização

cytoplasmic

Informações sobre genes

human ... F13A1(2162)

Descrição geral

Factor XIIIa is a plasma transglutaminase that is part of the blood coagulation cascade and plays a critical role in stabilizing fibrin networks at the site of an injury to produce a clot. Factor XIIIa is expressed in platelets, megakaryocytes, fibroblast-like cells in the placenta, uterus, and prostate, monocytes and macrophages, and dermal dendritic cells. Anti-Factor XIIIa immunohistochemistry is used to identify fibrohistiocytic neoplasms such as dermatofibroma.
Factor XIIIa is a blood proenzyme that has been identified in platelets, megakaryocyte, and fibroblast-like mesenchymal or histiocytic cells present in the placenta, uterus, and prostate; it is also present in monocytes and macrophages and dermal dendritic cells. Anti- Factor XIIIa has been found to be useful in differentiating between dermatofibroma (90% (+)), dermatofibrosarcoma protuberans (25%(+)) and desmoplastic malignant melanoma (0%(+)). Factor XIIIa positivity is also seen in capillary hemagioblastoma (100%(+)), hemangioendothelioma (100%(+)), hemangiopericytoma (100%(+)), xanthogranuloma (100%(+)), xanthoma (100(+)), hepatocellular carcinoma (93%(+)), glomus tumor (80%(+)), and meningioma (80 % (+)).

Qualidade


IVD
IVD
IVD
RUO

Ligação

Factor XIIIa Positive Control Slides , Product No. 251S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).

forma física

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide

Nota de preparo

Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.

Outras notas

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

Informações legais

Cell Marque is a registered trademark of Merck KGaA, Darmstadt, Germany

Não está encontrando o produto certo?  

Experimente o nosso Ferramenta de seleção de produtos.

Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number
1527310A-Z
1403408A-Z
1403407A-Z

Não está vendo a versão correta?

Se precisar de uma versão específica, você pode procurar um certificado específico pelo número do lote ou da remessa.

Pesquise por COA

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

M G Horenstein et al.
The American journal of surgical pathology, 24(7), 996-1003 (2000-07-15)
Routine histology and immunohistochemistry can usually distinguish dermatofibroma (DF) and dermatofibrosarcoma protuberans (DFSP). DF generally expresses factor XIIIa whereas DFSP generally expresses CD34. The authors report 10 cutaneous fibrohistiocytic lesions combining clinical, histologic, and immunohistochemical features of both DF and
P Abenoza et al.
The American Journal of dermatopathology, 15(5), 429-434 (1993-10-01)
To assess the use of anti-CD34 and anti-factor-XIIIa antibodies for the differential diagnosis of dermatofibroma (DF) and dermatofibrosarcoma protuberans (DFSP), we stained 40 DFs and 13 DFSPs. A significant population of dendritic and spindle cells was reactive with anti-factor-XIIIa in
Louis P Dehner
The American journal of surgical pathology, 27(5), 579-593 (2003-04-30)
Juvenile xanthogranulomas (JXG) is a histiocytic disorder, primarily but not exclusively seen throughout the first two decades of life and principally as a solitary cutaneous lesion. This study is a retrospective clinical and pathologic review of 174 cases documenting the
A J Demetris et al.
The American journal of surgical pathology, 21(3), 263-270 (1997-03-01)
Epithelioid hemangioendothelioma (EHE) is best considered a vascular neoplasm of intermediate malignancy. Although usually progressive, the clinical course is highly unpredictable. The present communication describes a case of extensive recurrent hepatic EHE, limited to the liver allograft and initially manifest
E J Glusac et al.
The American journal of surgical pathology, 18(6), 583-590 (1994-06-01)
Epithelioid cell histiocytoma is a recently recognized lesion that is considered to be a variant of cutaneous fibrous histiocytoma (dermatofibroma). Ten cases are presented, including their light microscopic, immunohistochemical, and ultrastructural features. Eight of the cases are similar to those
Exibir todos os documentos relacionados

Artigos

Immunohistochemistry: Current Applications in Skin Cancer

Immunohistochemistry (IHC) techniques and applications have greatly improved, dermatopathology is still largely based on H&E stained slides.This paper outlines ways in which IHC antibodies can be utilized for dermatopathology.

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica